A forum for researchers, students and applicants in the field of cyclodextrin technology
Rafael Holdings, Inc. (NYSE: RFL) announced on Oct. 29 that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug
The global, double-blind, placebo-controled Phase 3 TransportNPC™ study (CTD-TCNPC-301) enroled 94 patients with NPC, ranging in age from 3 to
Cyclodextrins (CDs) and their polymers are gaining momentum as advanced drug delivery systems. A recent review (https://www.sciencedirect.com/science/article/pii/S2590257125000203) highlights their progress
HP-β-CD is currently under clinical investigation for treating Niemann-Pick disease type C (NPC), but its ototoxicity remains problematic. It was
Niemann-Pick type C is a sever lysosomal storage disease, commonly refereed as ‘children’s Alzheimer’. There is no cure for it
Recent reviews emphasized the role of membrane lipids in the infectivity mechanism of SARS-COV-2. Cholesterol-rich parts of cell membranes serve
Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Cyclo
Strategic drug repurposing in combination with rapid testing of established molecular targets could provide a pause in disease progression and
Cyclo Therapeutics, Inc., a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
